Skip to main content
Clinical Trials/NCT05333952
NCT05333952
Recruiting
Not Applicable

A Randomized Controlled Study on the Waveform Periodicity Analysis of Complex Fractionated Electrograms in Patients With Persistent Atrial Fibrillation

Taipei Veterans General Hospital, Taiwan1 site in 1 country80 target enrollmentFebruary 19, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation, Persistent
Sponsor
Taipei Veterans General Hospital, Taiwan
Enrollment
80
Locations
1
Primary Endpoint
changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Atrial fibrillation (AF) has been the most frequently occurring, sustained arrhythmia, which causes significant morbidity and mortality. AF may not always be a totally random process. It can be maintained by stable and rapid reentrant circuits resulting in fibrillary conduction throughout the atria. During mapping of AF, difficulty is frequently encountered during the identification of culprit sites and an analysis of the wave propagation particularly when the electrogram signals demonstrate wide temporal and spatial disparities. Catheter ablation targeting regions with fractionated potentials or high frequencies during AF, has been previously proposed as a treatment strategy. However, the benefit of adjunctive CFAE (complex fractionated atrial electrogram) ablation or linear ablation after successful PVI (pulmonary vein isolation) was controversial based on the recent data from the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (STAR AF II) trial. Therefore, the optimal ablation strategy for persistent AF remains undetermined and an alternative approach has to be explored.

Detailed Description

In this prospective trial, investigators will investigate the long-term efficacy of catheter ablation of non-paroxysmal AF, based on selective atrial substrate modification (e.g. wavefrom periodicity analysis, similarity, plus phase mapping) (1). The control group would be PV isolation alone. The primary end point is long-term recurrence of atrial arrhythmias. The secondary end points composite procedural termination, the safety of the procedure, recurrence of multiple procedures, and change of atrial and ventricular function after catheter ablation. The inclusion criteria, exclusion criteria, stepwise catheter ablation procedures (PVI and then substrate modification), and the follow-up procedure are the same as current treatment approaches in patients with non-paroxysmal AF.

Registry
clinicaltrials.gov
Start Date
February 19, 2019
End Date
December 31, 2025
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patents who sign the informed consent forms, and allow to be followed.
  • Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication.
  • Patients with persistent/permanent AF (sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion).
  • Patients with age equal or greater than 20 years old regardless of gender.

Exclusion Criteria

  • The presence of a atrial or ventricular thrombus.
  • Patients who are allergic to or unsuitable for use with the contrast media.
  • Pregnant patients or patients who are unavailable to receive X-ray.
  • Patients with renal insufficiency.
  • Patients had autonomic nervous system disorder (e.g. respiratory apnea) or previous catheter ablation in the LA or MAZE procedure.
  • Patients who do not need atrial substrate modification (patients with non-paroxysmal AF respond to PVI in terms of procedural termination of AF).
  • Patients with age less than 20 years old or greater than 90 years old regardless of gender.

Outcomes

Primary Outcomes

changes in retention rate of normal sinus rhythm after catheter-based ablation of atrial fibrillation

Time Frame: Baseline and 3, 6, 9 and 12 months after catheter-based ablation of atrial fibrillation

A 24-hour Holter monitoring and/or ECG (7 days recordings) will be performed at 3, 6, 9, and 12 months post ablation and/or when the patients experience symptoms suggestive of a tachycardia after the ablation. Measurements: documentation of AF signal duration more than 30 seconds.

Secondary Outcomes

  • LVEF(after catheter ablation of atrial fibrillation 3, 6, 12 month)
  • e/e'(after catheter ablation of atrial fibrillation 3, 6, 12 month)
  • LAD(after catheter ablation of atrial fibrillation 3, 6, 12 month)

Study Sites (1)

Loading locations...

Similar Trials